Key Market Indicators
Korean diabetes medicine sales are set to reach $1.4 billion by 2026, a 2.9% year-on-year average rate increase from the 2021 figures of $1.2 billion. Since 2013, the market has grown 10.6% year-on-year. In 2021, South Korea ranked fifth, overtaken by Italy with $1.2 billion. Canada, Spain, and Italy respectively took the second, third, and fourth spots in the ranking. Korean insulin imports are set to reach $128 million by 2026, a 3.1% year-on-year average rate increase from the 2021 figures of $107 million. Since 1993, demand has grown 8.9% year-on-year.
